What a New Meta-Analysis Found About Tesamorelin and Visceral Fat

What Did This New Tesamorelin Meta-Analysis Analyse?

Researchers Ahmed Samy Badran, Abdulrhman Helal, Karim Samir Shata and Hazem Ayesh published a meta-analysis of tesamorelin clinical trial data in Obesity Research & Clinical Practice, an Elsevier journal.[1] The authors systematically searched the literature through July 2025 for randomised controlled trials comparing tesamorelin against placebo, then pooled the eligible trial data using standard meta-analytic methods.[1]

This is a pooled analysis of existing randomised trial data, not a new clinical trial. Its value is statistical: combining five separate trials increases the power to detect effects, and to distinguish outcomes with consistent evidence from those that remain inconclusive across the published literature.

What Did the Pooled Data Show for Visceral and Hepatic Fat?

The headline finding concerns visceral adipose tissue (VAT) — fat stored around the internal organs rather than under the skin. Across the pooled trials, tesamorelin was associated with a statistically significant reduction in VAT compared with placebo: a mean difference of −27.71cm² (95% CI −38.37 to −17.06; P<0.001).[1]

The hepatic fat finding is notable in its own right: tesamorelin's mechanism runs through pituitary GHRH-receptor signalling and the downstream GH/IGF-1 axis, not through a direct action on liver tissue, so a consistent reduction in hepatic fat percentage across pooled trials is a downstream metabolic signal rather than a primary drug target.

What Happened to Lean Mass and Metabolic Safety?

Alongside fat-mass reductions, the pooled data showed a statistically significant increase in lean body mass associated with tesamorelin.[1] That combination — falling fat mass alongside rising lean mass — is consistent with tesamorelin's proposed mechanism of restoring pulsatile GH secretion and downstream IGF-1 signalling, rather than a simple caloric-deficit effect.

Glucose tolerance has historically drawn scrutiny for GH-axis-active compounds, since growth hormone itself can be counter-regulatory to insulin. The absence of a significant glucose signal across five pooled trials is a relevant negative finding, not merely an absence of data.

Which Outcomes Did NOT Reach Statistical Significance?

A meta-analysis is only as informative as its negative findings. The pooled analysis found no statistically significant change in subcutaneous adipose tissue or in BMI associated with tesamorelin versus placebo.[1] That distinguishes this dataset's fat-redistribution profile from a generalised weight-loss effect: the pooled evidence points to a shift in where fat is stored (down in visceral and hepatic depots) rather than an overall reduction in body fat or scale weight.

This is a meaningful methodological detail. Reporting only the significant results would overstate what five pooled trials actually show; reporting the null BMI and subcutaneous-fat findings alongside the VAT result gives a more complete and more conservative picture of the pooled evidence.

How Does This Fit With the Original Tesamorelin Trial Data?

The foundational human data for tesamorelin comes from Falutz et al., a controlled trial published in the New England Journal of Medicine in 2007 that first reported reduced visceral adipose tissue in HIV-associated lipodystrophy with a GHRH-analogue.[2] This 2026 meta-analysis sits nearly two decades downstream, pooling that trial alongside four subsequent RCTs to test whether the original VAT-reduction finding holds up across a larger dataset — and, per the pooled result above, it does.

Our own Tesamorelin research overview covers the mechanistic case for why GHRH-receptor agonism is of research interest — pulsatile GH release, the cAMP signalling cascade, and the downstream IGF-1 axis. This meta-analysis is a useful pooled-evidence counterpart to that mechanistic framing, and for researchers comparing GHRH analogues directly, our CJC-1295 vs Tesamorelin guide sets out the structural and half-life differences between the two most-studied tools in this class.

What Should UK Researchers Take From This?

For researchers designing GH-axis studies, this meta-analysis is a useful reference point on where pooled clinical evidence is strongest for tesamorelin (visceral and hepatic fat, lean mass, an unchanged glucose safety profile) and where it remains flat (BMI, subcutaneous fat). It reports on clinical trial data for EGRIFTA, an FDA-approved medicine administered under medical supervision in a specific patient population — a separate question from research-use tesamorelin sold as a laboratory reagent. It has no bearing on the regulatory status of research-use peptides in the UK; see our guide on whether research peptides are legal in the UK for that separate question.

Velox Peptides supplies Tesamorelin strictly as an HPLC-verified in vitro research reagent, with batch documentation available on request and no dosing guidance of any kind. Researchers comparing GH-axis compounds against metabolic triple agonists in the current literature may also find our Retatrutide research-reagent listing relevant, alongside the broader somatotropic research category.

Tesamorelin is referenced here for research-news context only. Where supplied by Velox Peptides, it is a research reagent, not a medicine, and has not been evaluated by the MHRA or FDA in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions